Close Menu

More articles about Business News

The intellectual property, EP Application No 02702247.4, is derived from the so-called Kreutzer-Limmer III patent series developed by Germany’s Ribopharma, which Alnylam acquired in 2003 and later sold off to Roche.

IP Update: Sep 10, 2009

Premium

USPTO Publishes One Patent, Six Patent Applications Related to RNAi

The court determined that Alnylam and Max Planck have “not shown a substantial likelihood of success” on the merits of their case.

The allowed patent covers the use of multiple-promoter expression cassettes for simultaneous delivery of RNAi. Separately, the Aussie shop said the USPTO won’t likely decide a company appeal until the third quarter of next year.

Under the terms of the deal, Silence will “demonstrate the functional delivery” of its proprietary siRNA molecules, in combination with its in-house AtuPlex delivery technology, to certain undisclosed targets.

IP Update: Sep 3, 2009

Premium

USPTO Publishes Six Patents, Seventeen Patent Applications Related to RNAi

Under its new program, C-TASC will accept gene data from investigators in either raw or processed format and upload it to an online, searchable database, called StudyCTMS, which will be accessible to all researchers.

UMass further argued in its counterclaim that a key aspect of the disputed RNAi technology — the 3’ overhangs commonly incorporated into siRNAs — was an inherent feature of the RNAi molecules described in a patent application filed prior to another patent application from Max Planck that specifically claims the overhangs.

A Santaris official also said that while the company remains committed to microRNAs as drug targets, the company isn’t likely to advance additional miRNA drugs into the clinic in the near term as it takes a measured approach to selecting future clinical candidates.

The company also reported its financial results for the first half of 2009, posting a roughly 32 percent rise in revenues and a 28 percent jump in net losses.

IP Update: Aug 27, 2009

Premium

USPTO Publishes Three Patents, Ten Patent Applications Related to RNAi

The suit claims that Illumina's Genome Analyzer and related products and services infringe a patent originally issued to Genelabs and now held by a firm called LadaTech.

Even if it is able to obtain funding, the company said it may still shut its doors “if we believe the amount of additional funding would be insufficient to allow us to make meaningful progress in developing our current product candidates.”

While many firms have successfully met their goals of allying with big pharmas and biotechs, others have failed to do so, despite promises of forthcoming deals.

While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.

The disclosure comes about a month after the company announced that it had received clearance from Spanish regulators to begin the trial, in line with its previously disclosed guidance.

The arrangement gives Super Religare the rights to distribute the tests in India, Saudi Arabia, Qatar, and the United Arab Emirates.

The company expects its cash position, which was recently bolstered by an $8 million stock and warrant offering, to be sufficient to fund operations for at least 12 months.

IP Update: Aug 20, 2009

Premium

USPTO Publishes Three Patents, Twelve Patent Applications Related to RNAi

The distribution agreement covers the Duolink reagent line.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.